BIOPOR Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.1.80 |
| 52 Week High | kr.3.85 |
| 52 Week Low | kr.1.07 |
| Beta | 1.18 |
| 1 Month Change | 43.08% |
| 3 Month Change | -13.88% |
| 1 Year Change | 13.21% |
| 3 Year Change | -54.31% |
| 5 Year Change | -54.14% |
| Change since IPO | -99.22% |
Recent News & Updates
Recent updates
We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Dec 25
We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jun 28We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Feb 27Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
Oct 19We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate
Jun 15Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation
Oct 16Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
May 28BioPorto A/S' (CPH:BIOPOR) Path To Profitability
Mar 01We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jan 24A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration
Dec 20The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts
Nov 23
BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Nov 21Shareholder Returns
| BIOPOR | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 10.6% | 0.1% | 2.5% |
| 1Y | 13.2% | -14.7% | 27.5% |
Return vs Industry: BIOPOR exceeded the Danish Biotechs industry which returned -14.7% over the past year.
Return vs Market: BIOPOR underperformed the Danish Market which returned 27.6% over the past year.
Price Volatility
| BIOPOR volatility | |
|---|---|
| BIOPOR Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DK Market | 10.0% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: BIOPOR's share price has been volatile over the past 3 months.
Volatility Over Time: BIOPOR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 29 | n/a | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| BIOPOR fundamental statistics | |
|---|---|
| Market cap | kr.683.38m |
| Earnings (TTM) | -kr.53.82m |
| Revenue (TTM) | kr.32.38m |
21.1x
P/S Ratio-12.7x
P/E RatioIs BIOPOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOPOR income statement (TTM) | |
|---|---|
| Revenue | kr.32.38m |
| Cost of Revenue | kr.10.33m |
| Gross Profit | kr.22.04m |
| Other Expenses | kr.75.87m |
| Earnings | -kr.53.82m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 68.08% |
| Net Profit Margin | -166.23% |
| Debt/Equity Ratio | 0% |
How did BIOPOR perform over the long term?
See historical performance and comparison